Key facts
- This page summarizes Novo Holdings A/S's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Sep 2022, 14:35.
Novo Holdings A/S - 14 Sep 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- EWTX
- Reported as of
- 14 Sep 2022
- Net transaction value
- +$4,999,999
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2022, 14:35:28 UTC
- Prior SEC filing
- 22 Jul 2022
- Next SEC filing
- 03 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Barbara Fiorini Due, General Counsel of Novo Holdings A/S
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Novo Holdings A/S filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 16 Sep 2022.
Change
- Previous filing in this sequence was filed on 22 Jul 2022.
- Current net transaction value: +$4,999,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EWTX
transaction
COMMON STOCK
Purchase
- Transaction value
- $4,999,999
- Shares
- +484,496
- Change %
- +8.7%
- Price
- $10.32
- Shares after
- 6,071,703
- Date
- 14 Sep 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Novo Holdings A/S is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Represents a purchase from the underwriters in the Issuer's public offering.